Farmakoterapia w Psychiatrii i Neurologii

Pełna treść

1/2023 vol. 39
Artykuł przeglądowy

Sześćdziesiąt lat historii mechanizmu dopaminergicznego leków przeciwpsychotycznych

Janusz Rybakowski 1
  1. Department of Adult Psychiatry, Poznan University of Medical Sciences, Poznan, Poland; Klinika Psychiatrii Dorosłych, Uniwersytet Medyczny w Poznaniu, Poznań, Polska
Farmakoterapia w Psychiatrii i Neurologii 2023, 39 (1): 9-17
DOI: https://doi.org/10.5114/fpn.2023.127421
Data publikacji online: 2023/07/07
Plik artykułu
12R_IPiN_FARM_2023-1E_POPR_60 lat mechanizmu_Piśmiennictwo.popr.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Ashok AH, Marques TR, Jauhar, S, Nour MM, Goodwin GM, Young AH et al. The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. Mol Psychiatry 2017; 22: 666-679.
  2. Brannan SK, Sawchak S, Miller AC, Lieberman JA, Paul SM, Breier A. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021; 384: 717-726.
  3. Bunney WE Jr. The current status of research in the catecholamine theories of affective disorders. Psychopharmacol Commun 1975; 1: 599-609.
  4. Carlsson A. Biochemical and pharmacological aspects of Parkinsonism. Acta Neurol Scand Suppl 1972; 51: 11-42.
  5. Carlsson A. Antipsychotic drugs, neurotransmitters and schizophrenia. Am J Psychiatry 1978; 135: 165-173.
  6. Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on the formation of 3-methoxytyramine and normetanephrine on mouse brain. Acta Pharmacol Toxicol 1963; 20: 140-144.
  7. Carlsson A, Hansson LO, Waters N, Carlsson ML. A glutamatergic deficiency model of schizophrenia. Br J Psychiatry Suppl. 1999; 37: 2-6.
  8. Carlsson ML, Carlsson A, Nilsson M. Schizophrenia: from dopamine to glutamate and back. Curr Med Chem 2004; 11: 267-77.
  9. Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 2011; 378: 1306-1315.
  10. Darwish M, Bugarski-Kirola D, Passarell J, Owen J, Jaworowicz D, DeKarske D et al. Pimavanserin exposure-response analyses in patients with schizophrenia: results from the phase 2 ADVANCE study. J Clin Psychopharmacol 2022; 42: 544-551.
  11. Delay J, Deniker P, Harl J-M. Utilisation en thérapeutique psychiatrique d’une phénothiazine d’action centrale elective. Ann Méd-Psychol 1952; 110: 112-131.
  12. Divry P, Bobon J, Collard J, Pinchard A, Nois E. Etude et expérimentations cliniques du R 1625 ou halopéridol, nouveau neuroleptique et “neurodysleptique”. Acta Neurol Psychiatr Belg 1959; 59: 337-366.
  13. Earley W, Guo H, Daniel D, Nasrallah H, Durgam S, Zhong Y et al. Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data. Schizophr Res 2019; 204: 282-288.
  14. Fagius J, Osterman PO, Sidén A, Wiholm BE. Guillain-Barré syndrome following zimeldine treatment. J Neurol Neurosurg Psychiatry 1985; 48: 65-69.
  15. Fell MJ, McKinzie DL, Monn JA, Svensson KA. Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia. Neuropharmacology 2012; 62: 1473-1483.
  16. Jaracz J, Rybakowski J. Fluwoksamina – najdłużej stosowany lek z grupy selektywnych inhibitorów wychwytu serotoniny. Farmakoter Psychiatr Neurol 2006; 22: 167-175.
  17. Keltner NL, Johnson V. Biological perspectives. Aripiprazole: a third generation of antipsychotics begins? Perspect Psychiatr Care. 2002; 38: 157-159.
  18. Ketter TA, Miller S, Dell’Osso B, Wang PW. Treatment of bipolar disorder: Review of evidence regarding quetiapine and lithium. J Affect Disord 2016; 191; 256-273.
  19. Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 1995; 274: 329-336.
  20. Kuroki T, Nagao N, Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog Brain Res. 2008; 172: 199-212.
  21. Lee T, Seeman P. Dopamine receptors in normal and schizophrenic human brains. Soc Neurosci 1977; Abstr 3: 443.
  22. Mailman RB, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des. 2010; 16: 488-501.
  23. Meltzer HY. The importance of serotonin-dopamine interactions in the action of clozapine. Br J Psychiatry Suppl 1992; 17: 22-29.
  24. Möller HJ. Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1101-1111.
  25. Nasrallah HA, Fedora R, Morton R. Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist. Schizophr Res 2019; 208: 217-220.
  26. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nature Medicine 2007; 13: 1102-1107.
  27. Quiroz JA, Yatham LN, Palumbo JM, Karcher K, Kushner S, Kusumakar V. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry 2010; 68: 156-162.
  28. Rybakowski J. Aripiprazol – lek przeciwpsychotyczny trzeciej generacji. Ordynator Lek 2006; 6: 16-20.
  29. Rybakowski JK. Two generations of mood stabilizers. Int J Neuropsychopharmacol 2007; 10: 709-711.
  30. Rybakowski JK. Meaningful aspects of the term ‘mood stabilizer’. Bipolar Disord 2018; 20: 391-392.
  31. Rybakowski JK. Application of antipsychotic drugs in mood disorders. Brain Sciences 2023: 13: 414.
  32. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014; 511: 421-427.
  33. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261: 717-719.
  34. Siwek M, Wojtasik-Bakalarz K. Leki przeciwpsychotyczne. W: Psychofarmakologia kliniczna. Red. Rybakowski J. Państwowy Zakład Wydawnictw Lekarskich, Warszawa 2022, 109-175.
  35. Spiker DG, Perel JM, Hanin I, Dealy RS, Griffin SJ, Soloff PH et al. The pharmacological treatment of delusional depression: Part II. J Clin Psychopharmacol. 1986; 6: 339-342.
  36. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002; 71: 877-892.
  37. Tamminga CA. Partial dopamine agonist in the treatment of psychosis. J Neural Trnasm 2002; 109: 411-420.
  38. Tohen M, Calabrese JR, Sachs GS, Banov MD, Detke HC, Risser R et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar i disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006; 163: 247-256.
  39. Van Rossum JM. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther 1966; 160: 492-494.
  40. Yasuda Y, Kikuchi T, Suzuki S, Tsutsui M, Yamada K, Hiyama T. 7-[3-(4-[2,3-Dimethylphenyl]piperazinyl)propoxy]-2(1H)-quinolinone (OPC-4392), a presynaptic dopamine autoreceptor agonist and postsynaptic D2 receptor antagonist. Life Sci. 1988; 42: 1941-1954.
  41. Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010; 71: 150-162.
  42. Yunusa I, Rashid N, Seyedin R, Paratane D, Rajagopalan K. Comparative efficacy, safety, and acceptability of pimavanserin and other atypical antipsychotics for Parkinson's disease psychosis: systematic review and network meta-analysis. J Geriatr Psychiatry Neurol. 2023 Jan 31:8919887231154933. doi: 10.1177/08919887231154933. Online ahead of print.
  43. Zarate CA, Tohen M, Banov MD, Weiss MK, Cole JO. Is clozapine a mood stabilizer? J Clin Psychiatry 1995; 56: 108-112.
ZGŁASZANIE PRAC
Udostępnij
without publication fees
without publication fees
Zintergrowane z
Zasady redakcyjne
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications